First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival.
暂无分享，去创建一个
[1] W. Wilson,et al. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] X. Troussard,et al. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment , 2019, American journal of hematology.
[3] F. Ravandi,et al. How I manage patients with hairy cell leukaemia , 2017, British journal of haematology.
[4] Jeffrey A Jones,et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. , 2017, Blood.
[5] H. Kantarjian,et al. Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial , 2016, British journal of haematology.
[6] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[7] A. Rohatiner,et al. Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis , 2009, British journal of haematology.
[8] J. Koziol,et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.